AAVnerGene Announces AAVone®2.1, a Next-Generation Single-Plasmid AAV Production Platform Achieving ~1e16 GC/L and >70% Full Capsids at Harvest

AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® ...
Yonhap News Agency

[PRNewswire] AAVnerGene Announces AAVone®2.1

ROCKVILLE, Md. May 8, 2026 /PRNewswire=YONHAP/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the ...
BioProcess International

Accelerating AAV Process Development and Productivity: Using High-Throughput DoE and Small-Molecule Process Intensification

High-throughput virology, design of experiments, and small-molecule production enhancers optimize yield and increase ...
The Scientist

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...
GEN

Platform Processes May Reduce AAV Gene Therapy Costs

Gene therapies that are based on adeno-associated virus (AAV) vectors have demonstrated immense potential to treat and even cure previously intractable diseases, but unfortunately the costs are ...
GEN

Purification Option Eases the Bottlenecks in AAV Production

Adeno-associated viruses (AAVs) are used in nearly a dozen FDA-approved therapies and more than 900 R&D projects to deliver therapeutic payloads to cells. Yet, large-scale AAV production is still a ...
UMass Lowell

Ph.D. Dissertation Defense in Biomedical and Nutritional Sciences: Brandon Hoyle 6/25

Dhimiter Bello, Sc.D., M.Sc. (Chair) Jonathan Hill, Ph.D. (industry on site advisor) Soumita Das, Ph.D. Jonghan Kim, Ph.D. Brief Abstract: Adeno-Associated Virus (AAV) vectors are being used in the ...